Abstract
Ferroportin, a membrane protein belonging to the major facilitator superfamily of transporters, is the only vertebrate iron exporter known so far. Several ferroportin mutations lead to the so-called ferroportin disease or type 4 hemochromatosis, characterized by two distinct iron accumulation phenotypes depending on whether the mutation affects the activity of the protein or its degradation pathway. Through extensive molecular modeling analyses using the structure of all known major facilitator superfamily members as templates, multiple structural models of ferroportin in the three mechanistically relevant conformations (inward open, occluded, and outward open) have been obtained. The best models, selected on the ground of experimental data available on wild-type and mutant ferroportion, provide for the first time a prediction at the atomic level of the dynamics of the transporter. Based on these results, a possible mechanism for iron export is proposed.
Introduction
Ferroportin (Fpn), the only known mammalian iron exporter, is essential for transporting iron across the basolateral surface of enterocytes into the blood circulation system and for recycling iron in the reticuloendothelial system [1]. The synthesis of Fpn is regulated via the iron-responsive element/iron regulatory proteins system at the cellular level [2] and by hepcidin at the organism level [3, 4]. Hepcidin is a small peptide that plays a key role in the regulation of iron homeostasis by virtue of its ability to bind Fpn, and induce its internalization and subsequent degradation [3, 4]. The final effect is the inhibition of iron efflux from duodenal enterocytes, macrophages, and hepatocytes into the bloodstream [5, 6]. Hepcidin expression is probably transcriptionally regulated, although the exact mechanisms are not completely defined [4, 7, 8]. The hepcidin–Fpn axis is the principal regulator of extracellular iron homeostasis in health and disease [5].
In humans, Fpn mutations are associated with type IV hemochromatosis or “ferroportin disease.” Most mutations are “loss of function” as they affect plasma membrane localization or iron export ability, and lead to a phenotype characterized by a high serum ferritin concentration, relative plasma iron deficiency, and preferential iron retention in reticuloendothelial cells [9–12]. On the other hand, some “gain-of-function” mutations do not impair the function of Fpn but rather result in hepcidin resistance and in the anomalous retention of the active protein on the cell membrane. The pathological signatures are in this case different, with a high transferrin saturation and parenchymal iron overload [9, 10, 12–15].
The topology of Fpn has not been exactly defined; in fact, no experimental data are available up to now on Fpn three-dimensional structure. Structural bioinformatics analyses of Fpn revealed that the protein conforms to the general plan of the major facilitator superfamily (MFS) transporters [16]. This superfamily represents the largest group of secondary active membrane transporters and plays an important role in multiple physiological processes [17–19]. A canonical MFS fold comprises 12 transmembrane helices (TMs) that are organized into two folded domains, an N- and a C-terminal domain, each containing six consecutive TMs [20]. In turn, these two domains display a twofold pseudosymmetry related by an axis perpendicular to the membrane plane [20]. The rotation of one domain relative to the other allows the conformational changes necessary for the “alternate access mechanism” of transport. This is achieved through cycling from an “inward-open” to an “outward-open” conformation through an intermediated “occluded” conformation and vice versa [20].
Recently, two structural models of human Fpn have been obtained by independent groups [10, 21]. The first one, built by homology modeling based on another member of the MFS, corresponds to Fpn structure in the “occluded” state and allowed to prove the crucial role of Trp42 in both the iron transport mechanism and the binding of hepcidin [10]. Most recently, a second model of Fpn in the inward-open conformation has been obtained by ab initio modeling [21]. Analysis of this model allowed identifying a potential iron binding site, centered around residues Asp39 and Asp181, whose importance was confirmed through site-directed mutagenesis [21]. In the same study, an essential role in iron transport was also established for Asp325 and Arg466, although their involvement in the transport mechanism remained undefined [21].
In this work, we describe new structural models of Fpn obtained in the three mechanistically relevant conformations (inward open, occluded, and outward open). Fpn structure was modeled using as templates all the known structures of MFS members. Twenty-two different models have been obtained and analyzed in the context of known experimental data in order to select the best model for each conformation. The three models selected provide a prediction at the atomic level of the conformational changes occurring in Fpn during iron transport and allow proposing a possible mechanism for iron export.
Materials and methods
Molecular modeling
The structural models of Fpn were built using the ab initio/threading approach implemented in the I-TASSER pipeline [22–24].
This consists of four general steps. In the first step, the query sequence is threaded by LOMETS (Local Meta-Threading Server) through a representative Protein Data Bank (PDB) structure library to search for the possible folds compatible with the sequence of the protein of interest [22, 25]. In the second step, the sequence is divided into threading-aligned and threading-unaligned regions. Fragments derived from the threading-aligned regions are reassembled by replica-exchange Monte Carlo simulations [26], while the structure of unaligned regions is built by ab initio folding simulations [27]. Models are then refined in an iterative procedure that optimizes the free energy, the global topology, and the hydrogen-bonding network of the model [28].
In this work, I-TASSER was used specifying as templates all the known three-dimensional structures of the MFS transporters (22 structures; see Table 1). However, threading-based LOMETS restraints were also used with the purpose of modeling the unaligned regions as well as adjusting the reassembly of aligned regions. The overall quality of the 22 models generated by I-TASSER has been evaluated using PROCHECK [50] and the model quality parameter C-score provided in the I-TASSER output (Supplementary Materials Table S1). Further, to choose the best Fpn model in each of the functionally relevant conformations, the 16 models displaying a G-factor value greater than –0.5 (the PROCHECK G-factor threshold for good quality three dimensional structures) have been analyzed according to criteria derived from available experimental data that are described in detail in the Results section.
Known MSF transporters’ three-dimensional structures used as templates to build Fpn models in the three mechanistically relevant conformational states.
| Template structure | PDB code | Conformation | Refs. |
|---|---|---|---|
| GlcP | 4LDS | Inward | [29] |
| GlpT | 1PW4 | Inward | [30] |
| GLUT-1 | 4PYP | Inward | [31] |
| LacY | 1PV7 | Inward | [32] |
| NRT1.1 | 4OH3 | Inward | [33] |
| PepTSt (POT-family) | 4APS | Inward | [34] |
| PepTSo (POT-family) | 4TPH | Inward | [35] |
| XylE | 4QIQ | Inward | [36] |
| YbgH (POT-family) | 4Q65 | Inward | [37] |
| NarK | 4JR9 | Partially inward | [38] |
| NarU | 4IU9 | Partially inward | [39] |
| POT (POT-family) | 4IKV | Partially inward | [40] |
| NarU | 4IU9 | Inward partially occluded | [39] |
| XylE | 4JA3 | Inward partially occluded | [41] |
| PipT | 4JO5 | Inward occluded | [42] |
| EmrD | 2GFP | Occluded | [43] |
| PepTSo (POT-family) | 2XUT | Occluded | [44] |
| XylE | 4GBY | Occluded | [45] |
| Lacy | 4OAA | Outward partially occluded | [46] |
| MelB | 4M64 | Outward partially occluded | [47] |
| FucP | 3O7Q | Outward | [48] |
| YajR | 3WDO | Outward | [49] |
Note how no single transporter has been crystallized in all the three conformations.
Iron binding site detection
Prediction of the presence of iron binding sites has been carried out using the software LIBRA (Ligand Binding Site Recognition Application) in conjunction with a database of known iron binding sites derived from the PDB. LIBRA is based on a graph theory approach to find the largest subset of similar residues between an input protein and a collection of known binding sites [51].
Results
Using the template structures listed in Table 1, 22 different molecular models of Fpn were initially generated (Supplementary Material, Figure S1). All the models display the typical fold of MFS proteins with 12 TMs spanning the membrane and the N- and C-termini located on the intracellular side. For most of the models obtained, the overall quality is fairly good, as judged by PROCHECK analysis and C-score values (see Supplementary Material, Table S1). In fact, in 18 cases out of 22, the percentage of residues in the allowed regions of the Ramachandran plot is >97% and in 16 cases out of 22 the overall G-factor calculated by PROCHECK is ≥ –0.5, the threshold for high-quality three-dimensional structures [50]. Further, in 15 cases out of 22, the C-score is greater than –2.5, the typical range for molecular models being –5 to 2 [22].
In order to select the three best models representative of the inward-open, occluded, and outward-open conformation of Fpn, the 16 models with G-factor ≥ –0.5 were further screened according to the following experimentally derived considerations:
Asp39, Asp181, and Asp325, whose mutation completely abolishes the iron binding and transport ability of Fpn, form a putative iron binding site in the inward-open and occluded conformations. In a good model, these residues should be placed at a relative distance <14 Å, as observed in the structurally characterized iron binding sites [21].
Arg466 mutation significantly reduces the iron transport ability of Fpn and has been hypothesized to act as an “electrostatic switch,” which, upon iron binding, facilitates the inward to outward transition of Fpn [21]. To establish electrostatic interactions with iron, this residue should be located at a distance <10 Å (the typical Debye length in biological systems [52]), from the putative iron binding site in the inward-open and occluded conformations.
Most members of the MFS display a conserved sequence signature [Gly]+1 [Asp]+5 [Arg]+9, located at the level of the cytoplasmic loop connecting TM2 and TM3, which has been named Motif A [53]. The crystal structure of the MSF transporter YajR and mutational analyses indicated that Motif A is essential to stabilize the outward-open conformation through formation of a salt bridge between the Asp and Arg residues of the motif (see Ref. [54] and references therein). The Motif A sequence signature is conserved in Fpn and is formed by residues Gly80, Asp84, and Arg88. Thus, an additional criterion for Fpn best models selection has been the formation of a salt bridge between Asp84 and Arg88 in the outward-open conformation.
The three models that better conformed to these criteria were those built using as templates the Escherichia coli glycerol-3-phosphate transporter GlpT (Ref. [30]; PDB code 1PW4) for the inward-open conformation, the E. coli symporter proton:xylose XylE (Ref. [45]; PDB code 4GBY) for the occluded conformation, and the E. coli fucose transporter FucP (Ref. [48]; PDB code 3O7Q) for the outward-open conformation.
Figure 1 shows a schematic representation of the three models, which provide a prediction at an atomic level of the conformational changes occurring in Fpn during iron transport. In the inward-open conformation, the protein displays a wide channel accessible from the intracellular side, which closes approximately in the middle of the membrane plane at the level of residues Asp39 and Asp181. Interestingly, in this conformation, Asp325 forms a salt bridge with Arg466 with its carboxyl group facing away from the Asp39-Asp181 couple (Figure 2A). In the occluded conformation, the salt bridge is broken and Asp325 moves toward Asp39 and Asp181, forming a site characterized by a high density of negative charge (Figure 2B). Indeed, ligand binding sites detection, using the LIBRA application in conjunction with a database of structurally characterized iron binding sites (Ref. [51]; see Materials and methods for details), reveals that the substructure formed by His32, Asp39, Asp181, and Asn185 displays a stereochemistry very similar to that of the Fe(II) binding site of the metal transporter MntR [55] (Supplementary Material, Figure S2). In the outward-open model of Fpn, Asp39, Asp181, and Asp325 move away from each other, in agreement with the notion that when the protein takes up this conformation, the metal is released (Figure 2C).

Schematic representation of the structural models of Fpn in the inward-open (A), occluded (B), and outward-open (C) conformations.

Schematic representation of the Fpn putative iron binding site in the inward-open (top panel), occluded (center panel), and outward-open (bottom panel) conformations.
In the outward-open model, it is worthwhile to mention the presence of the canonical Motif A [Gly 80]+1, [Asp 84]+5, [Arg 88]+9, in which Gly80 allows tight packing of TM2 and TM11 and Asp84 establishes electrostatic interactions with the N-terminal end of TM11 (backbone nitrogen of Ile491) and Arg88 (Figure 3). These interactions are predicted to stabilize the outward-open conformation of Fpn, as observed for other members of the MFS.

Schematic representation of Motif A in the outward-open model of Fpn.
Discussion
The analysis of the Fpn models obtained in the three different functional conformations allows to rationalize the available experimental data and to formulate hypotheses on the role of specific residues in iron binding and translocation. It is worth remarking that, in the inward-open conformation, Asp325 is involved in a salt bridge with Arg466 with its carboxyl group facing away from the Asp39-Asp181 couple. Thus, in this conformation, binding of Fe(II) probably involves only the latter couple of residues. In the transition from the inward open to the occluded conformation, Asp325 moves away from Arg466 and toward the pair Asp39-Asp181. For the intrinsic methodological limits of modeling, the model has been obtained in the absence of iron and thus cannot fully represent the Fpn occluded state. However, the high negative charge density region observed in this conformation appears well fit to host an iron binding site. This hypothesis is in agreement with the experimental observation that mutations D39A, D181V, and D325A lead to significant impairment of both iron binding and iron efflux in cells transfected with the mutated Fpn [21]. Moreover, the mutation D181V has been found in members of Italian families affected by type 4 hemochromatosis [56], further confirming the crucial role of Asp181. The occluded Fpn model also supports the role of Arg466 as an electrostatic switch. In fact, while in the inward-open conformation, the arginine charge is stabilized by Asp325; in the occluded conformation, Arg466 has no charge partner and therefore is in a high energy state from an electrostatic viewpoint, being located in the partially desolvated protein interior. This high energy state could trigger the conformational change to the outward-open conformation in which, according to the corresponding Fpn model, Arg466 is fully solvent accessible. It must be considered that, in the presence of iron, the rupture of the Asp325-Arg466 salt bridge would be facilitated by electrostatic attraction of Asp325 toward the metal bound by the Asp39-Asp181 couple and electrostatic repulsion between the metal and the Arg466 guanidinium group. From this viewpoint, a very interesting observation is the stereochemical similarity detected between Fpn residues His32, Asp39, Asp181, and Asn185, and the Fe(II) binding site of the metal transporter MntR [55] (Supplementary Materials Figure S2). Interestingly, mutation of His32 in rat Fpn and mutation of Asn185 in human Fpn both lead to a nonfunctional protein [49, 57]. It appears thus likely that the site formed by His32, Asp39, Asp181, and Asn185 is the initial Fe(II) binding site whose coordination sphere would be completed by Asp325, driving the motion of TM1 toward TM7 and the transition from the inward open to the occluded state. This hypothesis is further supported by the fact that Asp39 and Asp325 are located in orthologous positions on TM1 and TM7 of two arginine residues (Arg45 on TM1 and Arg269 on TM7), which in the glycerol-3-phosphate antiporter GlpT are thought to drive the motion of TM1 toward TM7, and the transition from the inward-open to the occluded state, upon binding of the negatively charged glycerol-3-phosphate ligand [30].
Regarding the outward-open model, it is worthwhile discussing the presence of Motif A, formed by residues [Gly 80]+1, [Asp 84]+5, and [Arg 88]+9, which is essential to coordinate the conformational changes of MSF transporters [54]. The presence of this motif in Fpn helps to explain the association of mutations G80S and R88G with type IV hemochromatosis [58]. In fact, the outward-open model of Fpn indicates that mutation of Gly80 would impair the correct interdomain helix packing, while mutation of Arg88 would destabilize the outward-open conformation by disruption of the salt bridge with Asp84.
In conclusion, the Fpn models described in the present work, together with available experimental data on wild-type and mutant Fpn, allow hypothesizing the following mechanism of iron transport. In the inward-open conformation, iron would bind to the Asp39-Asp181 couple, His32, and Asn185, possibly contributing to metal chelation. Iron binding would attract toward the metal coordination sphere Asp325, driving the motion of TM1 toward TM7 and the transition to the occluded state. At the same time, rupture of the Asp325-Arg466 salt bridge and repulsion of Arg466 would occur, which would generate a high energy state due to the partially desolvated arginine charge. This high energy state would be relaxed upon transition to the outward-open state, facilitated by the electrostatic interactions formed within the Motif A. At this stage, iron ligands would move apart from each other and the metal released in the extracellular space.
At present, the available data do not allow to understand if a coupling mechanism for iron transport (symport or antiport) is at play in Fpn or iron is simply transported following its concentration gradient. However, the putative transport mechanism outlined above will be useful to inspire additional mutagenesis studies that can help clarify these aspects.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299–309.10.1016/S1097-2765(00)80425-6Search in Google Scholar
2. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008;28:197–213.10.1146/annurev.nutr.28.061807.155521Search in Google Scholar PubMed
3. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425–33.10.1182/blood-2011-01-258467Search in Google Scholar PubMed PubMed Central
4. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090–3.10.1126/science.1104742Search in Google Scholar PubMed
5. Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacol Ther 2014;146:35–52.10.1016/j.pharmthera.2014.09.004Search in Google Scholar PubMed
6. Luo X, Jiang Q, Song G, Liu YL, Xu ZG, Guo ZY. Efficient oxidative folding and site-specific labeling of human hepcidin to study its interaction with receptor ferroportin. FEBS J 2012;279:3166–75.10.1111/j.1742-4658.2012.08695.xSearch in Google Scholar PubMed
7. De Domenico I, Ward DM, Nemeth E, Vaughn MB, Musci G, Ganz T, et al. The molecular basis of ferroportin linked hemochromatosis. Proc Natl Acad Sci USA 2005;102:8955–60.10.1073/pnas.0503804102Search in Google Scholar PubMed PubMed Central
8. Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, et al. C/EBPα regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 2002;277:41163–70.10.1074/jbc.M202653200Search in Google Scholar PubMed
9. Pietrangelo A. The ferroportin disease. Clin Liver Dis 2014;3: 99–100.10.1002/cld.340Search in Google Scholar PubMed PubMed Central
10. Le Gac G, Ka C, Joubrel R, Gourlaouen I, Lehn P, Mornon JP, et al. Structure-function analysis of the human ferroportin iron exporter (SLC40A1): effect of hemochromatosis type 4 disease mutations and identification of critical residues. Hum Mutat 2013;34:1371–80.10.1002/humu.22369Search in Google Scholar PubMed
11. Mayr R, Janecke AR, Schranz M, Griffiths WJ, Vogel W, Pietrangelo A, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010;53:941–9.10.1016/j.jhep.2010.05.016Search in Google Scholar
12. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004;32:131–8.10.1016/j.bcmd.2003.08.003Search in Google Scholar
13. Fernandes A, Preza GC, Phung Y, De Domenico I, Kaplan J, Ganz T, et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood 2009;114:437–43.10.1182/blood-2008-03-146134Search in Google Scholar
14. Letocart E, Le Gac G, Majore S, Ka C, Radio FC, Gourlaouen I, et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol 2009;147:379–85.10.1111/j.1365-2141.2009.07834.xSearch in Google Scholar
15. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1:191–200.10.1016/j.cmet.2005.01.003Search in Google Scholar
16. Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol Cell Physiol 2010;298:C75–84.10.1152/ajpcell.00621.2008Search in Google Scholar
17. Foster DL, Boublik M, Kaback HR. Structure of the lac carrier protein of Escherichia coli. J Biol Chem 1983;258:31–4.10.1016/S0021-9258(18)33213-7Search in Google Scholar
18. Jin J, Guffanti AA, Beck C, Krulwich TA. Twelve-transmembrane-segment (TMS) version (ΔTMS VII–VIII) of the 14-TMS Tet(L) antibiotic resistance protein retains monovalent cation transport modes but lacks tetracycline efflux capacity. J. Bacteriol 2001;183:2667–71.10.1128/JB.183.8.2667-2671.2001Search in Google Scholar PubMed PubMed Central
19. Reddy VS, Shlykov MA, Castillo R, Sun EI, Saier MH Jr. The major facilitator superfamily (MFS) revisited. FEBS J 2012;279: 2022–35.10.1111/j.1742-4658.2012.08588.xSearch in Google Scholar PubMed PubMed Central
20. Yan N. Structural advances for the major facilitator superfamily (MFS) transporters. Trends Biochem Sci 2013;38:151–9.10.1016/j.tibs.2013.01.003Search in Google Scholar PubMed
21. Bonaccorsi di Patti MC, Polticelli F, Cece G, Cutone A, Felici F, Persichini T, et al. A structural model of human ferroportin and of its iron binding site. FEBS J 2014;281:2851–60.10.1111/febs.12825Search in Google Scholar PubMed
22. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER suite: protein structure and function prediction. Nat Methods 2015;12:7–8.10.1038/nmeth.3213Search in Google Scholar PubMed PubMed Central
23. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 2010;5:725–38.10.1038/nprot.2010.5Search in Google Scholar PubMed PubMed Central
24. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008;9:40.10.1186/1471-2105-9-40Search in Google Scholar PubMed PubMed Central
25. Wu S, Zhang Y. LOMETS: a local meta-threading-server for protein structure prediction. Nucleic Acids Res 2007;35:3375–82.10.1093/nar/gkm251Search in Google Scholar PubMed PubMed Central
26. Zhang Y, Kihara D, Skolnick J. Local energy landscape flattening: parallel hyperbolic Monte Carlo sampling of protein folding. Proteins 2002;48:192–201.10.1002/prot.10141Search in Google Scholar PubMed
27. Wu S, Skolnick J, Zhang Y. Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol 2007;5:17.10.1186/1741-7007-5-17Search in Google Scholar PubMed PubMed Central
28. Li Y, Zhang Y. REMO: a new protocol to refine full atomic protein models from C-α traces by optimizing hydrogen-bonding networks. Proteins 2009;76:665–76.10.1002/prot.22380Search in Google Scholar PubMed PubMed Central
29. Iancu CV, Zamoon J, Woo SB, Aleshin A, Choe JY. Crystal structure of a glucose/H+ symporter and its mechanism of action. Proc Natl Acad Sci USA 2013;110:17862–7.10.1073/pnas.1311485110Search in Google Scholar PubMed PubMed Central
30. Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 2003;301:616–20.10.1126/science.1087619Search in Google Scholar PubMed
31. Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, et al. Crystal structure of the human glucose transporter GLUT1. Nature 2014;510:121–5.10.1038/nature13306Search in Google Scholar PubMed
32. Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S. Structure and mechanism of the lactose permease of Escherichia coli. Science 2003;301:610–5.10.1126/science.1088196Search in Google Scholar PubMed
33. Sun J, Bankston JR, Payandeh J, Hinds TR, Zagotta WN, Zheng N. Crystal structure of the plant dual-affinity nitrate transporter NRT1.1. Nature 2014;507:73–7.10.1038/nature13074Search in Google Scholar PubMed PubMed Central
34. Solcan N, Kwok J, Fowler PW, Cameron AD, Drew D, Iwata S, et al. Alternating access mechanism in the POT family of oligopeptide transporters. EMBO J 2012;31:3411–21.10.1038/emboj.2012.157Search in Google Scholar PubMed PubMed Central
35. Guettou F, Quistgaard EM, Raba M, Moberg P, Löw C, Nordlund P. Selectivity mechanism of a bacterial homolog of the human drug-peptide transporters PepT1 and PepT2. Nat Struct Mol Biol 2014;21:728–31.10.1038/nsmb.2860Search in Google Scholar PubMed
36. Wisedchaisri G, Park MS, Iadanza MG, Zheng H, Gonen T. Proton-coupled sugar transport in the prototypical major facilitator superfamily protein XylE. Nat Commun 2014;5:4521.10.1038/ncomms5521Search in Google Scholar PubMed PubMed Central
37. Zhao Y, Mao G, Liu M, Zhang L, Wang X, Zhang XC. Crystal structure of the E. coli peptide transporter YbgH. Structure 2014;22:1152–60.10.1016/j.str.2014.06.008Search in Google Scholar PubMed
38. Zheng H, Wisedchaisri G, Gonen T. Crystal structure of a nitrate/nitrite exchanger. Nature 2013;497:647–51.10.1038/nature12139Search in Google Scholar PubMed PubMed Central
39. Yan H, Huang W, Yan C, Gong X, Jiang S, Zhao Y, et al. Structure and mechanism of a nitrate transporter. Cell Rep 2013;3:716–23.10.1016/j.celrep.2013.03.007Search in Google Scholar PubMed
40. Doki S, Kato HE, Solcan N, Iwaki M, Koyama M, Hattori M, et al. Structural basis for dynamic mechanism of proton-coupled symport by the peptide transporter POT. Proc Natl Acad Sci USA 2013;110:11343–8.10.1073/pnas.1301079110Search in Google Scholar PubMed PubMed Central
41. Quistgaard EM, Löw C, Moberg P, Trésaugues L, Nordlund P. Structural basis for substrate transport in the GLUT-homology family of monosaccharide transporters. Nat Struct Mol Biol 2013;20:766–8.10.1038/nsmb.2569Search in Google Scholar PubMed
42. Pedersen BP, Kumar H, Waight AB, Risenmay AJ, Roe-Zurz Z, Chau BH, et al. Crystal structure of a eukaryotic phosphate transporter. Nature 2013;496:533–6.10.1038/nature12042Search in Google Scholar PubMed PubMed Central
43. Yin Y, He X, Szewczyk P, Nguyen T, Chang G. Structure of the multidrug transporter EmrD from Escherichia coli. Science 2006;312:741–4.10.1126/science.1125629Search in Google Scholar PubMed PubMed Central
44. Newstead S, Drew D, Cameron AD, Postis VL, Xia X, Fowler PW, et al. Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2. EMBO J 2011;30:417–26.10.1038/emboj.2010.309Search in Google Scholar PubMed PubMed Central
45. Sun L, Zeng X, Yan C, Sun X, Gong X, Rao Y, et al. Crystal structure of a bacterial homologue of glucose transporters GLUT1-4. Nature 2012;490:361–6.10.1038/nature11524Search in Google Scholar PubMed
46. Kumar H, Kasho V, Smirnova I, Finer-Moore JS, Kaback HR, Stroud RM. Structure of sugar-bound LacY. Proc Natl Acad Sci USA 2014;11:1784–8.10.1073/pnas.1324141111Search in Google Scholar PubMed PubMed Central
47. Ethayathulla AS, Yousef MS, Amin A, Leblanc G, Kaback HR, Guan L. Structure-based mechanism for Na(+)/melibiose symport by MelB. Nat Commun 2014;5:3009.10.1038/ncomms4009Search in Google Scholar PubMed PubMed Central
48. Dang S, Sun L, Huang Y, Lu F, Liu Y, Gong H, et al. Structure of a fucose transporter in an outward-open conformation. Nature 2010;467:734–8.10.1038/nature09406Search in Google Scholar PubMed
49. Morris TJ, Litvinova MM, Ralston D, Mattman A, Holmes D, Lockitch G. A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis. Blood Cells Mol Dis 2005;35:309–14.10.1016/j.bcmd.2005.07.007Search in Google Scholar PubMed
50. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK – a program to check the stereochemical quality of protein structures. J App Cryst 1993;26:283–91.10.1107/S0021889892009944Search in Google Scholar
51. Viet Hung L, Caprari S, Bizai M, Toti D, Polticelli F. LIBRA: LIgand Binding site Recognition Application. Bioinformatics 2015. pii: btv489.10.1093/bioinformatics/btv489Search in Google Scholar PubMed
52. Benedek GB, Villars FM. Physics with illustrative examples from medicine and biology: electricity and magnetism. In: Greenbaum E, editor. Biological and medical physics biomedical engineering. New York: Springer-Verlag, 2000:403.Search in Google Scholar
53. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev 1996;60:575–608.10.1128/mr.60.4.575-608.1996Search in Google Scholar PubMed PubMed Central
54. Jiang D, Zhao Y, Wang X, Fan J, Heng J, Liu X, et al. Structure of the YajR transporter suggests a transport mechanism based on the conserved motif A. Proc Natl Acad Sci USA 2013;110: 14664–9.10.1073/pnas.1308127110Search in Google Scholar PubMed PubMed Central
55. McGuire AM, Cuthbert BJ, Ma Z, Grauer-Gray KD, Brunjes Brophy M, Spear KA, et al. Roles of the A and C sites in the manganese-specific activation of MntR. Biochemistry 2013;52:701–13.10.1021/bi301550tSearch in Google Scholar PubMed PubMed Central
56. Cremonesi L, Forni GL, Soriani N, Lamagna M, Fermo I, Daraio F, et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol 2005;131:663–70.10.1111/j.1365-2141.2005.05815.xSearch in Google Scholar PubMed
57. Zohn IE, De Domenico I, Pollock A, Ward DM, Goodman JF, Liang X, et al. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease. Blood 2007;109:4174–80.10.1182/blood-2007-01-066068Search in Google Scholar PubMed PubMed Central
58. Callebaut I, Joubrel R, Pissard S, Kannengiesser C, Gérolami V, Ged C, et al. Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients. Hum Mol Genet 2014;23:4479–90.10.1093/hmg/ddu160Search in Google Scholar PubMed
Supplemental Material:
The online version of this article (DOI: 10.1515/bams-2015-0034) offers supplementary material, available to authorized users.
©2016 by De Gruyter
Articles in the same Issue
- Frontmatter
- Research Articles
- The human iron exporter ferroportin. Insight into the transport mechanism by molecular modeling
- Is depth information and optical flow helpful for visual control?
- Human body posture as a source of information about selected diseases
- Evaluation of the training objectives with surface electromyography
- The effect of increasing amitriptyline doses on cardiomyocytes’ electrophysiology – simulation study
- Medical data preprocessing for increased selectivity of diagnosis
Articles in the same Issue
- Frontmatter
- Research Articles
- The human iron exporter ferroportin. Insight into the transport mechanism by molecular modeling
- Is depth information and optical flow helpful for visual control?
- Human body posture as a source of information about selected diseases
- Evaluation of the training objectives with surface electromyography
- The effect of increasing amitriptyline doses on cardiomyocytes’ electrophysiology – simulation study
- Medical data preprocessing for increased selectivity of diagnosis